desogestrel + ethinyl estradio tablet
nuvista pharma ltd - desogestrel + ethinylestradiol + ferrous fumarate - tablet - 150 mcg + 30 mcg + 75 mg
desogestrel+ethinyl estradiol tablet
popular pharmaceuticals ltd. - desogestrel + ethinylestradiol + ferrous fumarate - tablet - 150 mcg + 30 mcg + 75 mg
desogestrel/ethinyl estradiol
lupin limited - desogestrel; ethinyl estradiol - tablet; oral - 0.15mg/0.03mg
desogestrel 75microgram tablets
morningside healthcare ltd - desogestrel - oral tablet - 75microgram
desogestrel 75microgram tablets
medihealth (northern) ltd - desogestrel - oral tablet - 75microgram
desogestrel tablet
nuvista pharma ltd - desogestrel - tablet - 75 mcg
desogestrel 75microgram tablets
key pharmaceuticals ltd - desogestrel - oral tablet - 75microgram
caziant triphasic regimen- desogestrel and ethinyl estradiol kit
rpk pharmaceuticals, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - caziant (desogestrel and ethinyl estradiol tablets) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and implants, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year * method typical use † perfect use ‡ (1) (2) (3) (4) chance§ 85 85 spermicides¶ 26 6 40 periodic abstinence 25 63 calendar 9 ovulation method 3 sympto-thermal# 2 post-ovulation 1 withdrawal 19 4 capÞ parous women 40 26 42 nulliparous women 20 9 56 sponge parous women 40 20 42 nulliparous women 20 9 56 diaphragmÞ 20 6 56 condomß female
velivet triphasic regimen- desogestrel and ethinyl estradiol kit
rpk pharmaceuticals, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - velivet (desogestrel and ethinyl estradiol tablets) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and implants, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. table 2: percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year, united states. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year * method typical use † perfect use ‡ (1) (2) (3) (4) chance§ 85 85 spermicides¶ 26 6 40 periodic abstinence 25
reclipsen 28 day- desogestrel and ethinyl estradiol kit
rpk pharmaceuticals, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - reclipsen™ (desogestrel and ethinyl estradiol tablets usp) is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with reclipsen (desogestrel and ethinyl estradiol tablets usp), 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. table 1: percentage of women experiencing an unintended pregnancy during the first year of typi